The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 23, 2021

Filed:

Sep. 15, 2017
Applicant:

Bayer Pharma Aktiengesellschaft, Berlin, DE;

Inventor:

Martin Lange, Berlin, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5377 (2006.01); A61P 35/00 (2006.01); A61K 31/496 (2006.01); A61K 31/519 (2006.01); C07D 471/04 (2006.01); A61K 45/06 (2006.01); A61K 31/635 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5377 (2013.01); A61K 31/496 (2013.01); A61K 31/519 (2013.01); A61K 31/635 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 471/04 (2013.01);
Abstract

The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of PI3K kinase, and component B being venetoclax or palbociclib. Another aspect of the present invention relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment or prophylaxis of non-Hodgkin's lymphoma (hereinafter abbreviated to 'NHL'), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (hereinafter abbreviated to 'FL'), chronic lymphocytic leukaemia (hereinafter abbreviated to “CLL”), marginal zone lymphoma (hereinafter abbreviated to “MZL”), splenic marginal zone lymphoma (hereinafter abbreviated to “SMZL”), diffuse large B-cell lymphoma (hereinafter abbreviated to “DLBCL”), mantle cell lymphoma (MCL), transformed lymphoma (hereinafter abbreviated to “TL”), or peripheral T-cell lymphoma (hereinafter abbreviated to “PTCL”).


Find Patent Forward Citations

Loading…